OMN-6 is under clinical development by Omnix Medical and currently in Phase I for Ventilator Associated Pneumonia (VAP). According to GlobalData, Phase I drugs for Ventilator Associated Pneumonia (VAP) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OMN-6’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OMN-6 is under development for the treatment of multi-drug resistant Acinetobacter baumannii infections, hospital associated bacterial pneumoniae (HABP/VABP), blood-stream infections (BSI) and complicated urinary-tract infections (cUTI). It is administered through intravenous route. It acts by targeting bacterial membrane. The drug candidate is being developed based company’s technology which utilizes biochemical engineering to enable the synthesis of soluble, stable, safe and highly-potent antimicrobial-peptides.
Omnix Medical overview
Omnix Medical is a biopharmaceutical company that develops an arsenal of novel antibiotic agents for the treatment of infections involving drug-resistant bacteria. The company’s pipeline includes three programs such as OMN6 targeting Gram-negative bacteria, OMN-51 a new antimicrobial peptide (AMP) targeting Gram-negative bacteria like P. aeruginosa, and OMN-71 a antimicrobial peptide (AMP) targeting bacteria involved with skin infections in patients with Atopic-Dermatitis or Acne. Omnix Medical is headquartered in Jerusalem, Israel.
For a complete picture of OMN-6’s drug-specific PTSR and LoA scores, buy the report here.